1. Individualization of treatment strategies
- Author
-
Javier Cortés Castán, Sonia González Jiménez, Alicia García Arias, Laura Jolis López, Gemma Viñas Villaró, Xavier González Farré, Rafael Villanueva Vázquez, Adela Fernandez Ortega, and Cristina Saura Manich
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,Receptor, ErbB-2 ,Osteoporosis ,Psychological intervention ,Estrogen receptor ,Breast Neoplasms ,Pharmacology ,Disease-Free Survival ,Drug Administration Schedule ,Breast cancer ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,Pharmacology (medical) ,Neoplasm Invasiveness ,Aromatase ,Precision Medicine ,skin and connective tissue diseases ,Mastectomy ,Aged ,Neoplasm Staging ,Randomized Controlled Trials as Topic ,biology ,Dose-Response Relationship, Drug ,business.industry ,Aromatase Inhibitors ,Patient Selection ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,Tamoxifen ,Ki-67 Antigen ,Treatment Outcome ,Hormone receptor ,Chemotherapy, Adjuvant ,biology.protein ,Female ,business ,Body mass index ,Hormone - Abstract
This section focuses on different aspects of the individualization of hormone treatment in breast cancer. This includes tumor-related biological factors such as expression of hormone receptors, HER-2, and Ki-67; host-related factors such as CYP2D6 or body mass index, and risk and/or development of specific toxicities and treatment adherence. The best predictor of response to hormonal interventions is the expression of hormone receptors, in particular, estrogen receptors. Treatment adherence and compliance are key factors and strategies aiming to identify and intervene when patients are at risk of abandoning treatment. Currently, routine assessment of CYP2D6 is not recommended to guide tamoxifen treatment. Likewise, there are no criteria regarding bone mass density, lipid profile, or arthralgias to recommend one class of agent versus another. Aromatase inhibitors should not be administered to patients who are pre- or perimenopausal.
- Published
- 2011